FIBROMYALGIA TREATMENT MARKET ANALYSIS

Key Developments

• On March 06, 2024, Tonix Pharmaceuticals Holding Corp., a pharmaceutical company, announced that EVERSANA, a leading provider of commercialization services to the global life sciences industry, had been selected to support Tonmya's launch strategy and commercial planning in the U.S. EVERSANA will work with Tonix to examine the fibromyalgia landscape and develop an effective go-to-market strategy.
• On February 19, 2024, Tonix Pharmaceuticals Holding Corp. announced that it had reached an agreement with Rho Inc., a global contract research organization (CRO), to support its upcoming New Drug Application (NDA) to the FDA for Tonmya (cyclobenzaprine HCl sublingual tablets) to treat fibromyalgia patients.
• In January 2020, Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, reached an agreement with Pfizer Inc., a multinational pharmaceutical company, for an exclusive U.S. license to Pfizer's clinical and nonclinical data, as well as intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12, which Axsome is developing for the treatment of narcolepsy. The deal also grants Axsome exclusive rights to develop and commercialize esreboxetine, a novel late-stage pharmaceutical candidate known as AXS-14, in the U.S. for the treatment of fibromyalgia.